Causative Factors Involved in Development of Resistance to Tyrosine Kinase Inhibition and Novel Strategies Designed to Override This Resistance

Ellen Weisberg and James D. Griffin
Dana Farber Cancer Institute
USA

1. Introduction

This article describes original work performed in our laboratory related to the characterization of kinase inhibitors developed to treat myeloid leukemia, as well as identified mechanisms that likely contribute to resistance to kinase inhibition. Specifically, we provide detailed overviews of the kinase inhibitors nilotinib, used in the treatment of chronic myeloid leukemia (CML) and midostaurin, which is currently under investigation in late stage clinical trials for the treatment of mutant FLT3-positive acute myeloid leukemia (AML). Presented as well is a description of studies investigating strategies that leukemic cells employ to escape killing through kinase inhibition, including alterations in the expression and composition of targeted proteins and chemoresistance conferred by the bone marrow microenvironment. We provide a general overview of kinase inhibitors in preclinical and clinical development for CML and AML, and also discuss the use of combination therapy as an approach to enhancing the efficacy of tyrosine kinase inhibition and reducing the incidence of residual disease.

2. Development of BCR-ABL inhibitors and combination therapy studies geared toward overriding resistance to BCR-ABL inhibition

Imatinib resistance: Introduction

The development of resistance in leukemia patients to treatment with targeted tyrosine kinase inhibitors is a growing area of concern. For instance, the ABL inhibitor imatinib (STI571) (Druker et al., 1996; Buchdunger et al., 2001), which also inhibits KIT and platelet-derived growth factor receptor (PDGFR), has proven to be a highly effective, front line therapy for CML, a hematopoietic malignancy caused by the product of a reciprocal t(9;22) chromosomal translocation, BCR-ABL (Deininger et al., 2000). This targeted therapy has changed how newly diagnosed CML patients are treated and has substantially improved their prognosis. However, patients in the more advance phases of CML (namely, accelerated or blast crisis phase CML patients) often relapse due to drug resistance resulting from the emergence of imatinib-resistant point mutations within the BCR-ABL tyrosine kinase...
domain that reduce sensitivity towards imatinib (Gorre et al., 2001) or amplification of the target gene (Weisberg and Griffin, 2000).

Imatinib resistance and disease relapse in some patients can also be due to BCR-ABL-independent mechanisms, as exemplified by the small residual pool of BCR-ABL-positive quiescent leukemic stem cells existing in CML patients that have achieved complete responses after imatinib treatment. This inability of imatinib to completely eradicate quiescent leukemic stem cells occurs despite the high expression of BCR-ABL mRNA and protein in these cells (Michor et al., 2005; Roeder et al., 2006; Copland et al., 2006), which suggests that these leukemic stem cells are not dependent on BCR-ABL for viability. Therefore, a population of BCR-ABL-positive, quiescent stem cells continues to exist after imatinib therapy even in patients who have achieved complete responses, and the insensitivity of these cells to imatinib is believed to contribute to relapse observed in some patients following termination of imatinib treatment. The existence of this quiescent cell population is important to consider when attempting development of effective therapies for overriding intrinsic kinase inhibitor resistance and resistance due to stromal-mediated mechanisms. Such novel treatment approaches must be able to eradicate this cell population if maximum clinical benefit and complete disease-free survival is to be achieved.

Among strategies to override imatinib resistance are the direct targeting of the BCR-ABL protein and the targeting of mediators of signaling pathways downstream of BCR-ABL that are needed for transformation. Biorational drug design has led to the development of novel agents that overcome some forms of imatinib resistance, and impressive results obtained in clinical trials have led to rapid FDA approval of second generation compounds that are presently used to treat newly diagnosed CML patients.

**BCR-ABL point mutations as a mechanism of imatinib resistance**

Although early studies based on cell line models pointed toward BCR-ABL gene amplification and over-expression of BCR-ABL mRNA and protein as contributing to imatinib resistance (Weisberg and Griffin, 2000; Mahon et al., 2000; le Coutre et al., 2000), the most common mechanism of imatinib resistance was later discovered to be point mutations in the *BCR-ABL* gene that lead to changes in amino acids in the BCR-ABL protein catalytic domain. Of the mechanisms considered to be of major importance in the development of drug resistance, gene amplification accounts for approximately 10% of relapse in patients, whereas mutations in the kinase domain account for 40-90% of relapse in patients. Other important mechanisms include mutations or activation of other genes (i.e. Lyn) (Wu et al., 2008) and the contribution of organic cation transporter 1 or other related drug pumps (Engler et al., 2010). Mechanisms of minor importance or uncertain significance include the influence of multidrug resistance 1 gene (Gambacorti-Passerini et al., 2000) and alpha1 acidic glycoprotein (Mahon et al., 2000).

BCR-ABL point mutations, which diminish the binding of imatinib to its target, are often those that directly or indirectly impair the binding of imatinib to the BCR-ABL protein without compromising the function of the ABL tyrosine kinase domain. Point mutations that reduce imatinib binding through a direct mechanism are generally positioned around the imatinib binding site, and diminish imatinib binding through alterations in amino acid side chains or topographical changes that sterically hinder the binding of imatinib. Phe317 and Thr315 are examples of this type of BCR-ABL point mutation (Cowan-Jacob et al., 2004). Point mutations that reduce imatinib binding through an indirect mechanism utilize the distinct binding mode of a drug to BCR-ABL. Generally, there are three primary kinase
inhibitor binding modes that represent main mechanisms for pharmacological inhibition of kinase activity (Liu and Gray et al., 2006):

1. Kinase inhibitor directly competes with ATP in the ATP binding site. Inhibitors of this type are known as “Type I” and bind to the “Asp-Phe-Gly (DFG)-in” conformation (the “DFG” motif is highly conserved in protein kinases and sits near the beginning, or N-terminus, of the activation loop).

2. Kinase inhibitor engages an adjacent allosteric binding site, typically accessible when the activation loop and/or alpha-c helix is folded away from the binding site, which leads to kinase inactivation. Inhibitors of this type are known as “Type II” and bind to the “DFG-out” conformation.

3. Kinase inhibitor binds at sites distal from the ATP binding site. Imatinib, a “Type II” inhibitor, binds to the catalytically inactive conformation of the ABL kinase domain. BCR-ABL point mutations that destabilize the inactive conformations of the DFG motif diminish the binding capacity of imatinib, and therefore work through an indirect mechanism.

Over fifty different BCR-ABL point mutations have been identified (Roumiantssev et al., 2002; Von Bubnoff et al., 2002; Shah et al., 2002; Hochhaus et al., 2002) and generally fall into different categorical regions that include the hinge region (which bridges the C- and N-terminal lobes of the kinase domain to develop the ATP-binding cleft), A-loop, and P-loop (or “nucleotide-binding loop”). The position of the A-loop, which includes amino acids 381-402, regulates ABL kinase activity. Mutations in the A-loop typically confer moderate resistance. In contrast, P-loop mutations, which occur at the binding site for phosphates of ATP, include amino acids 244-255 of ABL, are highly imatinib-resistant, and confer a worse prognosis than other mutations (Soverini et al., 2005). Point mutations in the ABL kinase domain that destabilize the inactive conformations of the P-loop increase the free energy of the imatinib-ABL drug-protein complex, and in effect diminish imatinib binding. Gly250, Tyr 253, and Glu255 in the P-loop are examples of mutations that reduce imatinib binding through an indirect mechanism.

The vast majority of the BCR-ABL point mutations identified occur infrequently. Mutations such as those occurring at residues Thr315, Phe359, Met351, Gly250, Glu255, and Tyr253 comprise up to 70% of all existing mutations. It is possible that extremely rare levels of BCR-ABL point mutations pre-exist treatment with imatinib and increase in frequency during imatinib therapy (Roche-Lestienne et al., 2002; Hofmann et al., 2003).

In addition to detection of BCR-ABL point mutations in patients, BCR-ABL point mutations characterized as conferring imatinib resistance have been identified through *in vitro* random mutagenesis of BCR-ABL (Shah et al., 2002; Hochhaus et al., 2002). Some identified mutations were found to exist distal to the kinase domain, including the Src homology 2 (SH2) and SH3 domains and N-terminal cap region (Hochhaus et al., 2002; Azam et al., 2003; Pluk et al., 2002).

The detection of a point mutation in the BCR-ABL kinase domain was first reported in imatinib-resistant CML patients: three out of nine patients were characterized by BCR-ABL gene amplification, while six out of nine patients were characterized by an isoleucine substitution in the Thr315 residue located at the periphery of the nucleotide-binding site of ABL (also referred to as the “gatekeeper position”) (Gorre et al., 2001). The Thr315 residue, located in the hinge region, participates through a hydroxymethylene side chain in a critical H-bond interaction between imatinib and its protein target (Schindler et al., 2000; Manley et al., 2002; Nagar et al., 2002). Mutation of threonine to isoleucine confers resistance to
imatinib because of direct steric intrusion of the bulky isoleucine side chain, as well as loss of the hydrogen-bonding interaction in the ATP-cleft. An independent study of the crystal structure of an imatinib analog bound to ABL had shown Thr315 to be critical for the binding of imatinib to ABL, and the mutation of threonine to valine at this residue (T315V) was observed to confer imatinib resistance (Schindler et al., 2000; Corbin et al., 2002).

**Development of second generation BCR-ABL inhibitors designed to override imatinib resistance**

**Nilotinib**

As an approach to overriding imatinib resistance, we characterized and developed the phenylaminopyrimidine-based Type II ATP competitive inhibitor, nilotinib (NVP-AMN107-NX; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[4-3-pyridinyl]-2-pyrimidinyl]amino]benzamide), based on the crystal structures of inhibitors complexed with ABL (Cowan-Jacob et al., 2004). As with imatinib, another Type II ATP competitive inhibitor, part of nilotinib’s structure binds the ATP binding site, while part of its structure binds adjacent to the ATP binding site. Nilotinib was designed to fit into the ATP-binding site of BCR-ABL with higher affinity than imatinib, and demonstrates significantly higher potency than imatinib in inducing apoptosis of BCR-ABL-expressing cells (IC50<10 nM) by directly inhibiting ABL tyrosine kinase (Weisberg et al., 2005). Nilotinib also shows activity against a panel of imatinib-resistant BCR-ABL mutants, with the exception of T315I, and is effective in preventing the onset of leukemia in a BCR-ABL+ leukemic mouse model, and in prolonging the survival of mice harboring imatinib-resistant BCR-ABL-expressing cells (Weisberg et al., 2005; O’Hare et al., 2005). Crystallographic analysis of nilotinib complexed with ABL shows that, like imatinib, nilotinib binds to the inactive conformation of ABL. This suggests that the superior topographical fit to the ABL protein, as well as differences in the binding nature of nilotinib to ABL, contribute to the higher potency of nilotinib versus imatinib.

Clinical trial results with nilotinib in imatinib-resistant patients were favorable (Kantarjian et al., 2006; le Coutre et al., 2006; Ottmann et al., 2006). A phase III randomized, open-label multicenter study was conducted as a direct comparison of imatinib and nilotinib in CML patients. Results showed nilotinib to be superior to imatinib in patients with newly diagnosed chronic phase CML (Saglio et al., 2010). On October 29, 2007, the FDA granted accelerated approval to nilotinib for use in the treatment of chronic phase and accelerated phase Philadelphia chromosome positive (Ph+) CML in adult patients resistant or intolerant to prior therapy that included imatinib. On June 17, 2010, the FDA granted accelerated approval to nilotinib for treatment of adult patients with newly diagnosed Ph+ CML in chronic phase.

**Dasatinib**

Dasatinib (BMS-354825) is a second generation Type I ATP competitive inhibitor of BCR-ABL that is both a potent ABL inhibitor and a potent Src family kinase inhibitor (Shah et al., 2004; O’Hare et al., 2005; Burgess et al., 2005; Das et al, 2006; Melnick et al., 2006). Over-expression and activation of Src family kinases, such as LYN and HCK, have been shown to be associated with imatinib resistance (Donato et al., 2003), which suggests that the simultaneous targeting of BCR-ABL and Src family kinases may be effective in overriding resistance to imatinib. Unlike imatinib and nilotinib, which bind to the inactive conformation of BCR-ABL, dasatinib binds to the active conformation (Tokarski et al., 2006). Similar to nilotinib, dasatinib is effective against a number of imatinib-resistant BCR-ABL
point mutants, with the notable exception of the T315I gatekeeper mutant (Shah et al., 2004; O’Hare et al., 2005; Burgess et al., 2005).

Dasatinib received accelerated approval by the FDA in June 2006 and the European Medicines Agency (EMEA) in November 2006 for treatment of adults in all phase of CML with resistance or intolerance to imatinib treatment. This approval was based on positive results in early (Phase I and II) clinical trials (Talpaz et al., 2006; Cortes et al., 2007).

Dasatinib was also approved for treatment of drug-resistant Ph+ acute lymphoblastic leukemia (ALL) patients, in which a 190 kDa BCR-ABL protein is expressed resulting from an alternative breakpoint in the BCR gene. As with nilotinib, dasatinib has been granted FDA approval for therapy of newly diagnosed CML patients (Kantarjian et al, 2010).

Other BCR-ABL inhibitors

Dual ABL and Src inhibitors, bosutinib (SKI-606) (Puttini et al., 2006; Golas et al., 2003), which is a Type I ATP competitive inhibitor that only occupies the region normally occupied by ATP, and INNO-406 (first developed as NS-187) (Kimura et al., 2005), are active against a panel of imatinib-resistant BCR-ABL point mutants with the exception of the T315I gatekeeper mutant. AZD0530 is another dual ABL and Src inhibitor and Type I ATP competitive inhibitor that only weakly inhibits BCR-ABL (Lockton et al., 2005; Hennequin et al., 2006).

Aurora kinase inhibitors, which work through inhibition of the Aurora family of serine/threonine kinases, members of which are important for mitotic progression, represent another class of second generation inhibitors of BCR-ABL. Examples include PHA-739358 (Nerviano Medical Sciences) (Fancelli et al., 2006), which has been tested in early clinical trials in patients that relapsed after treatment with imatinib. PHA-739358 is a Type I inhibitor that binds the ATP binding site directly. Another example of an Aurora kinase inhibitor is MK-0457 (first developed as VX-680), which inhibits the proliferation of cells expressing the T315I-BCR-ABL gatekeeper mutant at submicromolar concentrations (Carter et al., 2005). MK-0457 has shown activity in some patients harboring the T315I mutation (Giles et al., 2007).

Non-ATP-competitive BCR-ABL inhibitors represent another class of second generation BCR-ABL inhibitors that work either via a non-ATP competitive allosteric mechanism or by prevention of substrate binding. Examples include ON012380, which shows potent activity against BCR-ABL-positive cells (Gumireddy et al., 2005). Compounds of this class make a covalent bond to the kinase and act as irreversible inhibitors. One complication is the fact that these compounds bind the substrate binding sites of multiple kinases, and therefore are very cytotoxic. Consequently, no clinical compound has been derived from this series. Non-ATP competitive inhibitors are also exemplified by the GNF2 and GNF5 family of inhibitors, which bind to the myristate binding site of BCR-ABL and inhibit its activity by stabilizing a catalytically less competent conformation of the protein (Adrian et al., 2006; Zhang et al., 2010). In addition, a type II inhibitor, GNF-7, has been shown to inhibit the T315I mutant in vitro and in vivo (Choi et al., 2010).

As an approach to overriding imatinib resistance, we developed and characterized HG-7-85-01, which is a Type II ATP competitive inhibitor that opens up a new chemical space in the field of kinase inhibitor development (Weisberg et al., 2010a). The structural inspiration for HG-7-85-01 is an amalgam of dasatinib and nilotinib, and is mostly utilization of the Type II nilotinib binding mode. Part of the structure of HG-7-85-01 binds to the ATP binding site, while the other part of its structure binds adjacent to the ATP binding site. In addition to
inhibiting T315I-BCR-ABL in CML, HG-7-85-01 was observed to inhibit gatekeeper mutants of multiple kinases of therapeutic interest including T670I c-Kit and T674I-PDGFRalpha, which are clinically observed in gastrointestinal stromal tumor (GIST) and hypereosinophilic syndrome (HEL). Despite this broad profile with respect to ‘gatekeeper’ mutant kinases, HG-7-85-01 is not a promiscuous inhibitor, and no other inhibitor has been reported to possess this biological profile. Demonstration that this multi-gatekeeper mutant profile can be achieved is very important to the field because many pharmaceutical companies are reluctant to develop inhibitors for drug-resistant mutant kinases as they do not believe a sufficient number of patients are likely to benefit. The biological profile of HG-7-85-01 demonstrates that a single compound could be developed that is capable of simultaneously targeting drug-resistant target kinases relevant across a range of malignancies.

Progress is being made toward development of pan-BCR-ABL inhibitors that target all identified BCR-ABL point mutants, including T315I-BCR-ABL gatekeeper mutation (the so-called “third generation” of BCR-ABL inhibitors). However, as the potential for emergence of new drug-resistant BCR-ABL point mutations still exists, benefit is likely to be gained from further development of BCR-ABL inhibitors displaying higher potency and distinct mutagenicity profiles, as well as therapeutic approaches involving administration of more than one BCR-ABL inhibitor or combined use of signal transduction inhibitors and BCR-ABL inhibitors.

**Combination therapy as an approach to overriding resistance to BCR-ABL inhibition**

As it was anticipated that, similar to imatinib, resistance to nilotinib and dasatinib would likely also emerge due to arising BCR-ABL point mutations in CML and Ph+ ALL, mutagenesis screens were performed to identify nilotinib- and dasatinib-resistant BCR-ABL point mutations and showed overlapping but distinct mutagenicity profiles (Von Bubnoff et al., 2006; Bradeen et al., 2006; Ray et al., 2007). There has been substantial interest in testing the notion that simultaneous or sequential administration of more than one ABL inhibitor might delay the onset of emergence of drug-resistant BCR-ABL point mutations. For instance, we have shown beneficial paired combinations of imatinib and nilotinib against imatinib-resistant CML (Weisberg et al., 2007a). Specifically, we demonstrate the synergistic interaction between nilotinib and imatinib against both non-mutated BCR-ABL and imatinib-resistant BCR-ABL point mutants. It has been suggested that the differential uptake mechanisms for imatinib and nilotinib may contribute to the observed synergy between the two agents (White et al., 2006). Alternatively, synergy may be explained by the ability of imatinib to increase the intracellular uptake and retention of nilotinib (and therefore its overall concentration), possibly through imatinib inhibition of ABCB1-mediated efflux of nilotinib (White et al., 2007). The demonstrated synergy between imatinib and nilotinib complements other published reports showing synergistic interaction between imatinib and the dual Src/Abl inhibitors, dasatinib and AP23848 (O’Hare et al., 2005), as well as synergistic interactions between imatinib and a panel of standard chemotherapeutic agents (Liu et al., 2002). In addition, combinations of dasatinib and imatinib have proven to be effective in diminishing the frequency of occurrence of drug-resistant BCR-ABL mutants, with the exception of T315I (Shah et al., 2004; Burgess et al., 2005; Bradeen et al., 2006; Talpaz et al., 2006). As improvement of disease-free survival could potentially be achieved from combination therapy involving inhibitors from the same or diverse structural classes, these studies could serve as a guide for further clinical investigation.
Since clonal resistance could potentially be overcome by combining two agents with different resistance profiles, we investigated the ability of HG-7-85-01 to positively combine with GNF-5, which is unable to potently inhibit T315I as a single agent (Zhang et al., 2010; Weisberg et al., 2010c). We demonstrated that combinations of HG-7-85-01 with GNF-5 have at least additive effects against both non-mutated BCR-ABL and BCR-ABL T315I \textit{in vitro} and \textit{in vivo} (Weisberg et al., 2010c). GNF-5 was also shown to enhance the activity of nilotinib against both non-mutated BCR-ABL and T315I-BCR-ABL \textit{in vitro} and \textit{in vivo} (Zhang et al., 2010).

An important characteristic of leukemia that confers survival advantages is the common deregulation of one or more of the three signaling pathways: PI3K/PTEN/Akt/mTOR, RAS/Raf/MEK/ERK, and Jak/STAT, each frequently activated by mutations in upstream genes. The redundancy and simultaneous/cross-activation between the three pathways warrants consideration of the use of a multi-targeted therapeutic strategy, or the use of more than one type of signaling inhibitor. We have shown that the dual PI3K/PDK-1 inhibitor, BAG956, has the ability to enhance the inhibitory effects of imatinib and nilotinib, respectively, to effectively kill BCR-ABL-expressing cells both \textit{in vitro} and \textit{in vivo} (Weisberg et al., 2008a). Similarly, enhanced apoptosis of BCR-ABL-positive cells has been found to result from treatment with a STAT5 inhibitor and imatinib or nilotinib (Nelson et al., 2011). In addition, inhibitors of MAPK and PI3K/Akt signaling have been implicated in up-regulation of proapoptotic BIM expression (Strasser et al., 2005). This is of potential importance with respect to imatinib resistance, as the proapoptotic BH3 domain-only protein, BIM, as well as proapoptotic BAD, mediate imatinib-induced apoptosis (Kuroda et al., 2006). Of relevance, the BH3 mimetic, ABT-737, overrides imatinib resistance due to loss of BIM and BAD (Kuroda et al., 2006). Inhibition of PI3K/Akt signaling also may be of potential benefit insofar as stromal-mediated chemoresistance is concerned, as Akt has been shown to be involved in leukemic cell survival in the bone marrow microenvironment (Tabe et al., 2007).

3. Development of inhibitors of FLT3, and combination therapy studies geared toward overriding resistance to FLT3 inhibition

\textit{Mutant FLT3 as a therapeutic target for AML}

The hematological malignancy, AML, is generally characterized by a block in cellular differentiation at different stages and aberrant proliferation of myeloid precursor cells. Early models have indicated that two types of mutations are responsible for the development of AML: One type of mutation is responsible for blocking terminal differentiation and the other type of mutation is responsible for promotion of growth and viability. However, full genome sequencing results suggest that up to 20 different mutations initiate AML, and disease development is thus likely more complicated than what the two mutation model proposes. Approximately 30\% of AML patients, as well as a portion of ALL patients, express a mutated form of the class III receptor tyrosine kinase, FLT3 (Fms-Like Tyrosine Kinase-3; STK-1, human Stem Cell Tyrosine Kinase-1; FLK-2, Fetal Liver Kinase-2) (Stirewalt and Radich, 2003). The existence of a FLT3 mutation generally translates into a poorer prognosis in terms of overall survival and disease-free survival (Mattison et al., 2007). The fact that FLT3 mutations are only found in a portion of AML cells suggests that FLT3 mutations may be involved in promotion of disease rather than initiation of disease.
The most prevalent form of constitutively activated FLT3, found in approximately 20-25% of AML patients (although in less than 5% of myelodysplastic syndrome patients), occurs as internal tandem duplications (ITDs) that are located within the juxtamembrane domain (Nakao et al., 1996; Horiike et al., 1997; Kiyoi et al., 1998; Kondo et al., 1999; Rombouts et al., 2000). This mutation has been shown to cause a rapidly lethal myeloproliferative disorder in mice in the absence of a block in differentiation, suggesting that its main role may be to cause hyper-proliferation of primitive myeloid cells (Kelly et al., 2002a). Mutant FLT3 is believed to interact with additional oncogenes that block differentiation, such as AML1/ETO (t(8;21)) PML/RARalpha (t(15;17)) to cause full leukemia development.

Occurring in approximately 7% of AML cases are gain-of-function FLT3 kinase domain point mutations, frequently at position 835 (Yamamoto et al., 2001). Also identified have been other kinase domain point mutations, including Y842C (Kindler et al., 2005) and N841I (Jiang et al., 2004). An activating point mutation with comparatively weaker transforming potential has also been discovered in a stretch of the FLT3 juxtamembrane domain (Reindl et al., 2006).

**Inhibitors of mutant FLT3**

There are several FLT3 inhibitors presently in clinical trials, and a number of novel agents under preclinical investigation. Unfortunately, the FLT3 inhibitors tested thus far clinically induce only partial and transient responses in patients—best when used as single agents. We identified and developed a small molecule inhibitor, the N-indolo-carbazole midostaurin (PKC412; N-benzoylstaurosporin), (Weisberg et al., 2002), a broad-spectrum first generation inhibitor that targets constitutively activated mutant FLT3. Other targets of midostaurin include (PDGFRbeta), c-KIT and c-FMS (Weisberg et al., 2002). Midostaurin showed high potency against mutant FLT3 as a target in vitro, and progressive leukemia was prevented in mice transplanted with marrow transduced with a FLT3-ITD-expressing retrovirus (Weisberg et al., 2002).

In early clinical trials, midostaurin administered in sequential and simultaneous combinations with standard chemotherapeutic agents such as daunorubicin and cytarabine induction and high-dose cytarabine consolidation yielded clinical responses with transient and/or reversible side effects (Stone et al., 2004). Midostaurin is one of several FLT3 inhibitors presently undergoing clinical testing, and it is currently under investigation in late stage clinical trials for AML.

We have demonstrated the activity of midostaurin against imatinib-resistant GIST (Weisberg et al., 2006). Specifically, we demonstrated the potent activity of midostaurin against cells expressing two PDGFRalpha mutants associated GIST: the V561D juxtamembrane domain mutation and the less imatinib-sensitive D842V kinase domain mutation. We also demonstrated the ability of nilotinib to positively combine with either imatinib or midostaurin against cells expressing the D842V-PDGFRalpha mutant. Findings reported introduce midostaurin as a potential treatment option for mutant PDGFRalpha-positive GIST and warrant its clinical testing for this disease target.

Additional multi-targeted inhibitors, such as dasatinib and the biaryl urea compound and first-generation inhibitor, sorafenib (BAY 43-9006), have been shown to have activity against mutant FLT3 and are under clinical investigation for AML (Auclair et al., 2007; Kancha et al., 2007; Lierman et al., 2007; Zhang et al., 2008; Metzelder et al., 2009; Guerrouahen et al., 2010). Other FLT3 inhibitors that have been clinically investigated and which elicited transient responses in early phase trials include the indolocarbazole alkaloid and first-
generation inhibitor, CEP-701 (lestaurtinib) (Levis et al., 2002; Smith et al., 2004; Knapper et al., 2006), KW-2449 (Pratz and Levis, 2008; Pratz et al., 2009; Shiotsu et al., 2009), 3-substituted indolinones SU5416 (Semaxanib) and SU5614 (Yee et al., 2002; Fielder et al., 2003; Giles et al., 2003; O’Farrell et al., 2004), the indolinone derivative and first-generation inhibitor, SU11248 (SU011248, sunitinib) (Fielder et al., 2005; Kancha et al., 2007; O’Farrell et al., 2003a,b), and the piperazinyl quinazoline and first-generation inhibitor, MLN518 (tandutinib; CT53518) (Kelly et al., 2002b; Cheng and Paz, 2008). Among FLT3 inhibitors in early development are the \( N-(4-(3\text{-amino}-1H\text{-indazol-4yl})\text{phenyl}-N^1(2\text{-fluoro}-5\text{-methylphenyl})\text{urea ABT-869 (Albert et al., 2006; Shankar et al., 2007; Zhou et al., 2008), the benzimidazole-quinoline CHIR-258 (TKI258) (Lopes de Menezes et al., 2005), the hydroxystyryl-acrylonitrile LS104 (Kasper et al., 2008) and AP24534 (Gozgit et al., 2011). AC220 (Chao et al., 2009; Zarrinkar et al., 2009) is a second-generation FLT3 inhibitor that exhibits significantly higher potency and selectivity than first-generation inhibitors, and is under clinical investigation for mutant FLT3-expressing AML and wild-type FLT3-harboring AML. A study by Pratz and colleagues suggested, however, that the potency and selectivity of agents targeting mutant FLT3 may not, in fact, be the best predictor of clinical efficacy (Pratz et al., 2010). In their study, AC220 was found to be the most potent inhibitor of several common FLT3 inhibitors tested (including lestaurtinib, midostaurin, sorafenib, and sunitinib) and had the highest index of selectivity. However, lestaurtinib- which had the lowest index of selectivity- was found to be the most effective when tested against FLT3-ITD-positive patient samples. Results shown in this study suggested that inhibition of FLT3 autophosphorylation in a FLT3-ITD specimen does not always induce death. For example, a side-by-side comparison of AC220 and lestaurtinib showed that while both compounds fully inhibited FLT3 autophosphorylation and suppressed downstream STAT5 activation in one patient sample, only lestaurtinib induced apoptosis. Relapsed AML samples were observed to be more sensitive to FLT3 inhibition than diagnostic AML, suggesting that some FLT3-ITD AML (i.e. diagnostic) may not be addicted to FLT3 signaling. This study suggested that more selective inhibitors, like AC220 may be less effective in the diagnostic setting while less selective inhibitors- like lestaurtinib or midostaurin- may be more effective at diagnosis.

**Resistance to FLT3 inhibition**

Thus far, none of the FLT3 inhibitors under clinical investigation has elicited a sustained clinical response when used as a single agent. As an example, a phase I clinical trial for KW-2449 showed that FLT3 inhibition in patients occurred only transiently to less than 20% of baseline levels (Pratz et al., 2009). It has been suggested that partial and transient FLT3 inhibition such as this applies to other FLT3 inhibitors in clinical development and may be responsible for their limited efficacy (Chu and Small, 2009).

One putative resistance mechanism related to FLT3 inhibition is dysregulation of signaling molecules, such as those associated with the PI3K/Akt and Ras/MEK/MAPK pathways (Piloto et al., 2007). Also implicated in drug resistance are aberrant STAT signaling (Zhou et al., 2009), the aberrant expression of the STAT5 target gene, PIM (Kim et al., 2005; Kim et al., 2006), and high levels of phosphoprotein expression of the forkhead transcription factor, FOXO3A (Kornblau et al., 2010). Additional mechanisms include up-regulation of anti-apoptotic proteins (Kohl et al., 2007; Brietenbuecher et al., 2009; Stolzel et al., 2010), up-regulation of inhibitors of apoptosis proteins, and elevated FLT3 ligand levels (Zhou et al., 2009). The concentration of FLT3 ligand has been observed to be significantly higher in
patients treated with chemotherapy or radiotherapy (Lyman et al., 1995; Wodnar-Filipowicz et al., 1996; Zwierzina et al., 1999; Bojko et al., 2002), and this is predicted to impede the action of FLT3 inhibitors administered after chemotherapy.

Another possible resistance mechanism is cytoprotection conferred by the bone marrow microenvironment. Indeed, FLT3 inhibition was found to actually enhance the survival of CD34+CD38-CD123+ leukemic stem cells and progenitor cells in a “niche-like” *in vitro* microenvironment that was comprised of factors including IL-6, IL-3, stem cell factor (SCF), and immobilized fibronectin (Mony et al., 2008). Small molecule CXCR4 inhibitors may be effective in enhancing kinase inhibitor-induced apoptosis of stromal-protected leukemic cells, implicating a causal relationship between the chemokine receptor CXCR4 and stroma-derived factor 1alpha (SDF-1a) interaction and drug-resistant leukemia (Zeng et al., 2006).

Pre-existing or acquired point mutations in the FLT3 kinase domain that interfere with drug binding may also contribute to drug resistance in patients (Cools et al., 2004; Heidel et al., 2006).

Point mutations in the FLT3 receptor are generally analogous to point mutations in BCR-ABL, the most prevalent mechanism of resistance to imatinib. However, there is little evidence for the existence of overlapping resistance profiles for FLT3 inhibitors, such as those demonstrated for imatinib, dasatinib, and nilotinib with respect to the T315I gatekeeper mutation (Von Bubnoff et al., 2006; Bradeen et al., 2006; Ray et al., 2007). Instead, non-overlapping mechanisms of resistance between PKC412, sorafenib, and SU5614 were found in a screening assay designed to study drug resistance profiles (Von Bubnoff et al., 2009). For example, SU5614 resistance was characterized predominantly as mutations in the D835 residue, while sorafenib resistance was characterized by unique mutations such as F691L and point mutations in the Y842 residue (Von Bubnoff et al., 2009). Another study confirmed the involvement of acquired mutations, D835N and Y842H, in resistance to SU5614 (Bagrintseva et al., 2004). In contrast, PKC412 resistance was characterized by mutations in the N676 residue, which was previously identified and characterized in a PKC412-resistant AML patient as the sole determinant of drug resistance (Heidel et al., 2006).

In addition to non-overlapping mutagenicity profiles between existing FLT3 inhibitors, each shows variable activity toward different mutations, for example activation loop mutants versus ITD mutations. As an example, sunitinib inhibits ITD and activation loop mutants with equal potency, whereas sorafenib is less efficacious toward activation loop mutants than ITD (Kancha et al., 2007). PKC412 shows comparable activity against different FLT3 activation loop mutants, whereas MLN518 shows variable activity (Clark et al., 2004; Barry et al., 2007).

*Combination therapy as an approach to treating mutant FLT3-positive disease*

As responses of patients to FLT3 inhibition is generally only partial and transient, there is a need for development of novel agents that can either be used effectively alone or combined with FLT3 inhibitors to suppress disease progression and prolong lifespan. FLT3 inhibitors have been tested in combination with standard chemotherapy agents as an approach to assessing the overall efficacy of combined therapies. For example, SU11248, combined with cytarabine or daunorubicin, exhibited additive-to-synergistic inhibitory effects on cells expressing mutant FLT3 (Yee et al., 2004). Similarly, CEP-701 showed synergy when combined with etoposide, mitoxantrone, daunorubicin, and cytarabine (Levis et al., 2004). PKC412 demonstrated synergy when combined with vincristine, 4-hydroperoxy-
Causative Factors Involved in Development of Resistance to Tyrosine Kinase Inhibition and Novel Strategies Designed to Override This Resistance

4. Characterization of underlying mechanisms of stroma-mediated chemoresistance to tyrosine kinase inhibition

In addition to identifying and developing potent kinase inhibitors representative of novel and unique structural classes with the ability to override drug resistance due to changes in the target protein, there is a push toward gaining a better understanding of the mechanisms underlying drug resistance in CML and AML as they relate to the leukemic cell microenvironment. Bone marrow is comprised of hematopoietic and stromal cells, in addition to other factors including extracellular matrix and blood vessels; growth factors...
and cell:cell interactions (Charbord et al. 1996). Bone marrow stroma and factors derived from stroma have been suggested to play a role in the long-term survival and proliferation of normal and leukemia cells (Ashley et al., 1994; Bradstock et al., 1996; Rafii et al., 1997; Lagneaux et al., 1998, Lagneaux et al., 1999; Konopleva et al., 2002; Litwin et al., 2002). Specifically, bone marrow stroma provides signals, such as granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), and terminal differentiation of hematopoietic stem cells or mediate/support their proliferation (Verfaillie et al., 1993; Liesveld et al., 1996; Harrison et al., 1997; Breems et al., 1997; O’Prey et al., 1998; Leslie et al., 1998; Shih et al., 1999). SSpenic stroma, as well, has been implicated in enhanced survival of both normal and leukemic cells (Shaked et al., 2005; Despars and O’Neill, 2006).

Clinical trial data with tyrosine kinase inhibitors show that while the peripheral blood of patients responds well, bone marrow responds less well. It appears possible that small numbers of leukemic CD34+ cells can persist in the marrow microenvironment of leukemia patients after years of therapy with kinase inhibitors. Stromal cells have been implicated, as they provide viability signals to leukemic cells that protect them from inhibitor effects. Indeed, the quantity of leukemic stem cells that rely on stroma to survive is predictive of disease outcome (Kumagai et al., 1996).

We revealed highest tumor burden and residual disease to occur in vivo in stroma-associated tissues in imatinib/nilotinib-treated NCr nude mice, suggesting that significant reservoirs for tumor growth appear to be tissues that are able to support normal hematopoietic and malignant stem cell development (Weisberg et al., 2008c). These studies, which showed a pattern of leukemia distribution consistent with what is observed in imatinib- and nilotinib-treated chronic myeloid leukemia patients, were followed by a more in-depth analysis of stroma-leukemia cell interactions that lead to protection of leukemia cells from nilotinib-induced cytotoxicity. For the latter, we used the human BCR-ABL-positive cell line, KU812F, and the human bone marrow stroma cell line, HS-5, to more closely approximate the bone marrow-associated cytoprotection observed in drug-treated leukemia patients. Partial stromal-mediated protection of BCR-ABL-positive leukemic cells from nilotinib treatment involved the cooperative interaction of members of a select panel of stromal-secreted viability factors, including IL-6 and GM-CSF (Weisberg et al., 2008c). Similar results were observed with mutant FLT3-positive leukemia cells treated with midostaurin in the presence of HS-5-stromal-conditioned media versus the same panel of stromal-secreted viability factors (Weisberg et al., 2009).

5. Potentiation of anti-leukemic effects of tyrosine kinase inhibitors by IAP inhibition: Implications for use of IAP inhibition to prevent or reduce residual disease following tyrosine kinase inhibition

Deregulated signaling molecules associated with viability/apoptotic signaling represent attractive targets for therapeutic intervention, and several strategies have emerged that may be effective in preventing drug resistance due to this. One approach involves combining targeted inhibitors with small molecule inhibitors of key components of major signaling pathways affecting the viability/expansion of leukemic cells. Accordingly, we have developed effective inhibitors of the inhibitor of apoptosis (IAP) family of proteins (Liu et al., 2000; Wu et al., 2000), such as LBW242 (Weisberg et al., 2007b), and its structural analog, LCL161, which bind to and inhibit multiple IAPs (i.e. XIAP, c-IAP) to enhance the activity of different proapoptotic signaling pathways. We have demonstrated the ability of LBW242 to
synergize with midostaurin \textit{in vivo} against progressive mutant FLT3-positive leukemia and to override stromal-mediated chemoresistance \textit{in vitro} (Weisberg et al., 2007b). Clinical trial data with midostaurin show that while good responses are achievable in mutant FLT3-positive AML patient peripheral blood, patient bone marrow responses are more modest. This suggests that stromal cells provide viability signals to AML cells that protect the cells from the effects of the selective inhibitor being used. We investigated the responsiveness of Ba/F3-FLT3-ITD cells cultured in the presence and absence of WEHI (used as a source of IL-3) to the cytotoxic effects of midostaurin, and we found that the presence of IL-3 completely protected cells from midostaurin-inhibition of cellular proliferation (Weisberg et al., 2007b). In contrast to midostaurin, the IAP inhibitor, LBW242, inhibited Ba/F3-FLT3-ITD proliferation in both the absence and the presence of IL-3 (Weisberg et al., 2007b). Interestingly, LBW242 plus midostaurin inhibited the growth of Ba/F3-FLT3-ITD cells cultured in the presence of IL-3 to a greater extent than either agent alone; this inhibition was similar to that achieved with co-administration of both agents in the absence of IL-3, suggesting that an IAP inhibitor is able to enhance the effects of a FLT3 inhibitor and override chemoresistance due to provision of viability signals (Weisberg et al., 2007b).

In an attempt to more closely model putative stromal-AML cell interactions and stromal-mediated viability signaling effects on the cytotoxic effects of midostaurin, we tested the human stroma cell line, HS-5, in combination with the mutant FLT3 AML line, MOLM-13-luc+ (luciferase was used to specifically quantify only the leukemia component in the assay using light emission). A confluent layer of HS-5 stromal cells enhanced the growth of MOLM13-luc+ cells and was partially protective against the inhibitory effects of midostaurin (Weisberg et al., 2007b). LBW242 enhanced the cytotoxic effects of midostaurin against MOLM13-luc+ cells in the presence of HS-5 human stromal cells, supporting the notion that stromal-mediated viability signals may contribute to chemoresistance to FLT3 inhibitors (such as midostaurin) observed in marrow, as well as the idea that such resistance may be overcome by inclusion of IAP inhibitor treatment (Weisberg et al., 2007b). We have also shown the ability of LCL161 to significantly delay disease recurrence in mice injected with BCR-ABL-expressing cells and treated for several weeks with a moderate dose of nilotinib (Weisberg et al., 2010d). Specifically, using \textit{in vitro} models of intrinsic drug resistance and stromal-mediated chemoresistance, as well as functional mouse models of progressive and residual disease, we showed the ability of the novel IAP inhibitor, LCL161, to enhance the cytotoxic effects of tyrosine kinase inhibitors against leukemic disease. Importantly, we observed LCL161 to synergize \textit{in vivo} with nilotinib to reduce leukemia burden significantly below the baseline level suppression exhibited by a moderate-to-high dose of nilotinib. Our results support the idea of using IAP inhibitors in conjunction with targeted tyrosine kinase inhibition to suppress or eradicate progressive and drug-resistant or residual disease. Phase I studies in advanced solid tumors are currently ongoing, and LCL161 is being considered for testing in clinical trials for leukemia.

\textbf{6. Conclusion}

Elucidation of mechanisms of resistance to tyrosine kinase inhibition is critical for the optimization of existing therapies and prolongation of patient survival via delaying or eradicating the recurrence of disease. For CML, the discovery and characterization of BCR-ABL point mutations in the kinase target of a number of inhibitors in clinical use has been a
tremendous step forward in understanding an important underlying mechanism of drug resistance. While second generation BCR-ABL inhibitors, such as nilotinib and dasatinib, have proven to be highly effective in the clinic and override imatinib resistance to an extent, the existence of highly imatinib-resistant mutants, such as the T315I gatekeeper mutant, is a limiting factor. Even for third generation BCR-ABL inhibitors that are able to override T315I, the potential exists for the evolution of novel drug-resistant point mutations that impede the binding of drug to its target. Thus, there continues to be a need for development of BCR-ABL inhibitors with high potency and unique mutagenicity profiles, as well as a continued need for combination therapy approaches to overriding drug resistance.

For mutant FLT3-positive AML, due to the only transient and partial effects observed clinically with FLT3 inhibitors in late-stage development, there is an urgent need for the development of new treatment approaches that could potentially lead to improved clinical effectiveness. As with CML, the key to improved patient responsiveness may lie in continued development of compounds conferring a higher degree of potency, as well as novel combination therapy strategies.

For both CML and mutant FLT3-positive AML, elucidation of mechanisms of resistance that are associated with leukemic cell survival, such as stromal-mediated chemoresistance and up-regulation of viability signaling molecules, warrants the investigation of single agent activity of pro-apoptotic agents. It also warrants the development of treatment approaches that rely on administration of kinase inhibitors combined with other agents targeting components of leukemia:stromal cell interactions and stromal-derived viability factors.

7. References


Causative Factors Involved in Development of Resistance to Tyrosine Kinase Inhibition and Novel Strategies Designed to Override This Resistance


can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood, Aug 1;100(3), pp. 1014–1018.


The current book comprises a series of chapters from experts in the field of myeloid cell biology and myeloid leukemia pathogenesis. It is meant to provide reviews about current knowledge in the area of basic science of acute (AML) and chronic myeloid leukemia (CML) as well as original publications covering specific aspects of these important diseases. Covering the specifics of leukemia biology and pathogenesis by authors from different parts of the World, including America, Europe, Africa, and Asia, this book provides a colorful view on research activities in this field around the globe.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
